Additionally, Fedratinib, a Janus kinase-2 inhibitor (JAK2 inhibitor), can prevent the generation of TH17-mediated cytokine storm; therefore may improve the clinical condition of severely affected COVID-19 patients. Here, JAK2 is linked to COVID-19.